NEW YORK (GenomeWeb News) – Molecular diagnostics firm Inostics announced today that its clinical laboratory in Baltimore, Md., has received CLIA licensure, allowing it to offer its non-invasive OncoBeam tumor mutation test.

The blood-based test is based on Beaming — or Beads, Emulsions, Amplification, and Magnetics — technology that combines emulsion-based digital PCR with flow cytometry. Inostics said the technology allows for the molecular analysis of tumor DNA shed from primary and metastatic tumors found circulating in a patient's blood.

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

In Nature this week: Icelandic genome sequences, approach to increase CRISPR efficiency, and more.

Testing showing "genetic incompatibilities" have led thousands of couples in Saudi Arabia to call off their weddings, the BBC reports.

Decode Genetics' ability to tell Icelanders, even ones the company hasn't sequenced, about their disease risk brings up ethical questions.

Genetic analysis of Britain's King Richard III and modern descendants of his relatives indicate breaks in the male line.